Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicines set out in the Schedule hereto:
Schedule
Product: Active Ingredient:
Dosage Form: New Zealand Sponsor: Manufacturer:
|
Noradrenaline Tartrate Noradrenaline acid tartrate monohydrate 0.12g/L equivalent to noradrenaline base 0.06 g/L Solution for infusion Biomed Limited Biomed Limited, Auckland, New Zealand
|
Note: This renewed consent is valid for two years from 2 December 2017.
Product: Active Ingredient:
Dosage Form: New Zealand Sponsor: Manufacturer:
|
Noradrenaline Tartrate Noradrenaline acid tartrate monohydrate 0.199g/L equivalent to noradrenaline base 0.1 g/L Solution for infusion Biomed Limited Biomed Limited, Auckland, New Zealand
|
Note: This renewed consent is valid for two years from 2 December 2017.
Product: Active Ingredient:
Dosage Form: New Zealand Sponsor: Manufacturer:
|
Noradrenaline Tartrate Noradrenaline acid tartrate monohydrate 0.239g/L equivalent to noradrenaline base 0.12 g/L Solution for infusion Biomed Limited Biomed Limited, Auckland, New Zealand
|
Note: This renewed consent is valid for two years from 2 December 2017.
Product: Active Ingredient:
Dosage Form: New Zealand Sponsor: Manufacturer:
|
Noradrenaline Tartrate Noradrenaline acid tartrate monohydrate 0.319g/L equivalent to noradrenaline base 0.16 g/L Solution for infusion Biomed Limited Biomed Limited, Auckland, New Zealand
|
Note: This renewed consent is valid for two years from 2 December 2017.
Dated this 2nd day of November 2017.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).